For patients with small cell lung cancer, chest radiotherapy increases survival, decreases recurrence
the ONA take:
According to a new study published in The Lancet, patients with advanced small cell lung cancer (SCLC) experienced prolonged survival and reduced recurrence of the disease after being treated prophylactic cranial radiotherapy plus thoracic radiotherapy compared with those treated with prophylactic cranial radiotherapy alone.
In the phase 3 clinical study, researchers enrolled 498 adults with advanced SCLC who had already responded to first-line chemotherapy from 42 hospitals in Europe. Patients were randomized to receive either prophylactic cranial radiotherapy plus chest radiotherapy or prophylactic cranial radiotherapy alone. Radiation was administered over 2 weeks and patients were followed for an average of 2 years.
The researchers found that patients survival rates were similar between both groups after 1 year, but they found that after 2 years, 13% of patients treated with combination radiotherapy were alive, while only 3% of those treated with prophylactic cranial radiotherapy were alive. In addition, 20% those who received combination radiotherapy experienced recurrence in the thoracic region compared with 46% of the cranial radiotherapy group.
The authors suggest that chest radiation therapy should be considered as a treatment approach in patients with extensive small cell lung cancer who have responded to first-line chemotherapy.
SCLC patients experienced prolonged survivalafter being treated prophylactic cranial radiotherapy.
For patients with advanced small cell lung cancer, thoracic radiotherapy alongside standard treatment may boost long-term survival and reduce the likelihood of cancer recurrence in the chest, according to researchers.
Small cell lung cancer (SCLC) accounts for around 10-15% of all lung cancer cases. It is almost always caused by smoking and tends to spread rapidly to other parts of the body, meaning it is often diagnosed in its advanced stages.
- Physical Activity Improves Outcomes for Patients with Breast Cancer and Survivors
- Behavior Pain Assessment Tool Measures Pain In Patients Who Cannot Communicate Verbally
- Whole Genome Sequencing Reveals that 12% of Childhood Cancer Survivors Have Mutations in Genes that Increase Cancer Risk
- Increased 5-Year Survival Rate Seen in NSCLC Subset Treated With Nivolumab
- Novel Test For Multiple Myeloma Uses Microchip, Conventional Blood Sample
- Exercise, Psychological Interventions Better for Cancer Fatigue Than Medications
- ASCO Issues Global Guidance for HPV Vaccination for Cervical Cancer Prevention
- Discharge Events Improved With Standardized Inpatient Palliative Care Consultation
- Little Opposition to Early Palliative Care for Symptom Management in Pediatric Oncology
- Updated ASTRO Guideline Bolsters Safety, Efficacy of Palliative RT for Bone Metastases
- Thyroid Cancer Incidence Increasing Among Younger, Hispanic, African American Populations
- JAK1, JAK2 Inhibition Improves Outcomes in Myeloproliferative Neoplasms, But More Is Needed
- Recommendations Against Contralateral Prophylactic Mastectomy Not Tied to Patient Satisfaction
- Self-efficacy Level Predictive of Likelihood to Follow Through With Colorectal Cancer Screening
- Chronic Myeloproliferative Neoplasms Treatment (Fact Sheet)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|